Evidence map›Paper›PMID 35028452›Full record

ArticleHeliyon2022

DREAM, a possible answer to the estrogen paradox of the Women's Health Initiative Trial.

Judith C Hugh, Lacey S J Haddon, John Maringa Githaka, Gilbert Bigras, Xiuying Hu, Brittney Madden, John Hanson, Zsolt Gabos, Nadia V Giannakopoulos, Fleur Huang and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Judith C HughDepartment of Laboratory Medicine and Pathology, University of Alberta, 116 St & 85 Ave, Edmonton, Alberta T6G 2R3 Canada.
Lacey S J HaddonDepartment of Laboratory Medicine and Pathology, University of Alberta, 116 St & 85 Ave, Edmonton, Alberta T6G 2R3 Canada.
John Maringa GithakaDepartment of Biochemistry, University of Alberta, 116 St & 85 Ave, Edmonton, Alberta T6G 2R3 Canada.
Gilbert BigrasDepartment of Laboratory Medicine and Pathology, University of Alberta, 116 St & 85 Ave, Edmonton, Alberta T6G 2R3 Canada.
Xiuying HuDepartment of Psychiatry, University of Alberta, 116 St & 85 Ave, Edmonton, Alberta T6G 2R3 Canada.
Brittney MaddenDepartment of Laboratory Medicine and Pathology, University of Alberta, 116 St & 85 Ave, Edmonton, Alberta T6G 2R3 Canada.
John HansonDepartment of Oncology, University of Alberta, 116 St & 85 Ave, Edmonton, Alberta T6G 2R3 Canada.
Zsolt GabosDepartment of Oncology, University of Alberta, 116 St & 85 Ave, Edmonton, Alberta T6G 2R3 Canada.
Nadia V GiannakopoulosDepartment of Laboratory Medicine and Pathology, University of Alberta, 116 St & 85 Ave, Edmonton, Alberta T6G 2R3 Canada.
Fleur HuangDepartment of Oncology, University of Alberta, 116 St & 85 Ave, Edmonton, Alberta T6G 2R3 Canada.
Mary M HittDepartment of Oncology, University of Alberta, 116 St & 85 Ave, Edmonton, Alberta T6G 2R3 Canada.
Kirk J McManusDepartment of Oncology, University of Manitoba, 675 McDermot Avenue, Winnipeg, Manitoba R3E 0V9, Canada.
David OlsonDepartment of Oncology, University of Alberta, 116 St & 85 Ave, Edmonton, Alberta T6G 2R3 Canada.
Kelly DabbsDepartment of Oncology, University of Alberta, 116 St & 85 Ave, Edmonton, Alberta T6G 2R3 Canada.
John R MackeyDepartment of Oncology, University of Alberta, 116 St & 85 Ave, Edmonton, Alberta T6G 2R3 Canada.
University of Alberta · CAUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Estrogen is thought to cause proliferation of all estrogen receptor positive (ER+) breast cancers. Paradoxically, in the Women's Health Initiative Trial, estrogen-only hormone replacement therapy reduced the incidence and mortality of low grade, ER+, HER2- breast cancer. We gave estradiol to 19 post-menopausal women with newly diagnosed low-grade, ER+, HER2- breast cancer in a prospective window of opportunity clinical trial and examined the changes in proliferation and gene expression before and after estradiol treatment. Ki67 decreased in 13/19 (68%) patients and 8/13 (62%) showed a decrease in Risk of Recurrence Score. We chose three prototypical estrogen responders (greatest decrease in ROR) and non-responders (no/minimal change in ROR) and applied a differential gene expression analysis to develop pre-treatment (PRESTO-30

Indexed as

Breast cancerDREAMEstrogenHormone therapy

Identifiers

PMID35028452
PMCPMC8741439
OpenAlexW4200485780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.